Hydrogel Scaffolds for Corneal Repair: Advances, Clinical Relevance, and Guideline-Based Insights

Abstract

Hydrogel scaffolds have emerged as a promising technology for corneal repair, offering potential solutions to the limitations of conventional grafting and transplantation. Driven by an increasing demand for corneal tissue and advances in biomaterials science, hydrogel scaffolds provide a supportive microenvironment for cellular regeneration and integration, while minimizing immunogenic responses. This review synthesizes current evidence regarding the design, mechanisms, clinical applications, recent advances, and guideline-based recommendations for hydrogel scaffolds in corneal repair, with particular focus on their functional outcomes, safety profile, and future prospects in clinical ophthalmology.

Introduction

Corneal blindness remains a leading cause of visual impairment worldwide, with millions affected by trauma, infectious keratitis, dystrophies, and degenerative diseases. The global shortage of donor corneas, limitations of allografts, and transplantation failure due to immune rejection or graft opacity highlight the urgent need for alternative strategies. Hydrogel scaffolds, designed to mimic the extracellular matrix (ECM) of the native cornea, have shown promise in supporting corneal cell growth and tissue regeneration. This article delineates the scientific and clinical landscape of hydrogel scaffolds, discussing their structure-function relationships, therapeutic applications, and translational potential in corneal repair.

Epidemiology / Disease Burden

Corneal diseases account for an estimated 5–12% of all cases of blindness globally. The World Health Organization recognizes corneal opacities as a major cause of vision loss, particularly in lower-resource settings where infectious keratitis, trauma, and chemical burns are prevalent. The annual demand for corneal grafts far exceeds supply, with less than one cornea available for every 70 needed. This imbalance underscores the clinical imperative for alternative regenerative approaches, such as tissue-engineered scaffolds, to address the unmet needs in corneal repair.

Pathophysiology

The cornea's avascular, highly organized stromal matrix is critical for transparency and refractive function. Injury or disease can disrupt the epithelium, stroma, or endothelium, triggering inflammatory and fibrotic cascades that compromise optical clarity. Traditional grafts may fail due to immune rejection, delayed epithelialization, or stromal scarring. Hydrogel scaffolds, composed of natural or synthetic polymers, aim to recapitulate the ECM's mechanical and biochemical characteristics, fostering cellular adhesion, migration, and differentiation, thereby facilitating organized tissue regeneration and functional recovery.

Risk Factors

Patients at increased risk for corneal damage include those with ocular trauma, chemical exposure, infectious keratitis (bacterial, viral, fungal), hereditary dystrophies, and autoimmune disorders. Additional risk factors encompass previous ocular surgeries, contact lens misuse, and environmental hazards. These populations stand to benefit most from innovative repair strategies, including hydrogel-based scaffold interventions, particularly when conventional transplantation is contraindicated or unavailable.

Clinical Features

Corneal injury or disease manifests with pain, photophobia, lacrimation, reduced visual acuity, and visible opacification. Chronic non-healing ulcers, recurrent erosions, and persistent epithelial defects increase the risk for stromal melting and perforation. Timely, effective corneal repair is critical to prevent permanent vision loss, highlighting the need for advanced therapeutic modalities capable of restoring both anatomical integrity and functional vision.

Diagnosis

Diagnosis of corneal pathology relies on slit-lamp biomicroscopy, fluorescein staining, anterior segment optical coherence tomography (AS-OCT), and confocal microscopy. Assessment of defect depth, stromal involvement, and endothelial function informs therapeutic decisions. Biomaterial-based interventions require meticulous patient selection and preoperative evaluation to ensure suitability for scaffold implantation, particularly in cases of active infection or severe inflammation.

Treatment & Management

Standard treatment of corneal defects includes topical antibiotics, lubricants, autologous serum, and, in severe cases, amniotic membrane transplantation or keratoplasty. Hydrogel scaffolds represent a paradigm shift, providing structural support and a conducive microenvironment for endogenous or exogenously seeded cells. Hydrogels, such as those based on collagen, gelatin, hyaluronic acid, polyethylene glycol (PEG), and silk fibroin, can be engineered for tailored mechanical properties, degradation rates, and bioactivity. Clinical protocols often involve scaffold implantation with or without limbal stem cells, with postoperative management focused on epithelialization monitoring and infection prevention.

Recent Advances / Emerging Therapies

Recent advances include the development of biomimetic hydrogels with tunable transparency, mechanical strength, and biofunctionalization for enhanced cell adhesion and proliferation. Injectable hydrogels and in situ crosslinking approaches enable minimally invasive delivery and conformal defect coverage. Incorporation of growth factors, anti-inflammatory agents, and antimicrobial peptides further augments regenerative potential and reduces complications. Preclinical and early-phase clinical studies demonstrate promising outcomes in terms of graft integration, transparency, and restoration of visual function, with ongoing trials evaluating long-term efficacy and safety.

Guideline Recommendations

While formal guideline recommendations for hydrogel scaffold use in corneal repair are evolving, consensus statements from ophthalmic societies endorse their consideration in cases where conventional grafting is unfeasible, contraindicated, or at high risk of failure. Patient selection should be individualized, with thorough exclusion of active infection, careful handling of scaffolds to maintain sterility, and close postoperative monitoring. Integration of hydrogel scaffolds into clinical practice warrants multidisciplinary collaboration, standardized protocols, and participation in registries to further refine indications and optimize outcomes.

Conclusion

Hydrogel scaffolds represent a transformative innovation in corneal repair, with the potential to overcome limitations of donor tissue availability and transplantation failure. Continued advances in biomaterials design, cellular engineering, and translational research are expanding the therapeutic armamentarium for corneal blindness. Rigorous clinical evaluation, adherence to evolving guidelines, and ongoing surveillance of long-term outcomes will shape the future of hydrogel scaffolds in ophthalmic practice, ultimately improving vision and quality of life for patients with corneal disease.